RecruitingPHASE2, PHASE3NCT03818334

Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies

Studying Rare disorder potentially indicated for transplant or complication after transplantation

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Hospital Israelita Albert Einstein
Principal Investigator
Andreza A Feitosa Ribeiro, PhD
Hospital Israelita Albert Einstein
Intervention
Cyclophosphamide(drug)
Enrollment
50 enrolled
Eligibility
1-75 years · All sexes
Timeline
2018 – 2026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03818334 on ClinicalTrials.gov

Other trials for Rare disorder potentially indicated for transplant or complication after transplantation

Additional recruiting or active studies for the same condition.

See all trials for Rare disorder potentially indicated for transplant or complication after transplantation →

← Back to all trials